We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Mutations Identified for Cowden Syndrome

By LabMedica International staff writers
Posted on 03 Jan 2013
Two new genes have been identified that are associated with Cowden syndrome (CS), an under-diagnosed condition that carries high risks of breast, thyroid, and other cancers.

The discovery of these genes will promote diagnosis and clinical management of CS while also assisting in predictive genetic testing and genetic counseling for a disease that is difficult to recognize and is characterized by small, noncancerous growths. More...


Scientists at the Cleveland Clinic (Cleveland, OH, USA) performed genetic sequencing on DNA from individuals with CS who have none of the known genetic alterations associated with CS. State-of-the-art technology was used to identify a high prevalence of mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) and the alpha serine/threonine-protein kinase (AKT1) genes, which are involved in cancer-related signaling pathways.

Germline mutations in the phosphatase and tensin homolog (PTEN) gene were found to cause 85% of CS when data from tertiary academic centers was analyzed. However, prospective data from the community over the last 12 years has revealed a 25% PTEN mutation frequency. PTEN is the phosphatase that has been implicated in a heritable cancer syndrome and subsequently in multiple sporadic cancers and developmental processes.

The investigators found that 8 of 91 (8.8%) unrelated CS individuals without germline PTEN mutations carried 10 germline PIK3CA mutations and 2 (2.2%) had AKT1 mutations. These mutations result in significantly increased phosphorylation of AKT on the activation residue Thr308 (P-Thr308-AKT) and increased cellular phosphatidylinositol (3,4,5)-triphosphate (PIP3). These results suggest that PIK3CA and AKT1 are CS susceptibility genes.

Charis Eng, MD, PhD, who is the Founding Director of the Lerner Research Institute's Genomic Medicine Institute (Cleveland, OH, USA) said, “Gene-enabled risk assessment and management begins with the identification of all the genes that, when mutated, account for as many or all the individuals with a particular syndrome, in this case CS. We started with only PTEN, and now we know that succinate dehydrogenase complex, subunit B, iron sulfur (SDHB/D), killin, p53-regulated DNA replication inhibitor (KLLN), PIK3CA, and AKT1 account for CS. Each also brings differing risks of breast, thyroid, and other cancers, and so this discovery directly aids genetic counseling and clinical management.” Cowden syndrome is a rare autosomal dominant inherited disorder characterized by multiple tumor-like growths called hamartomas and an increased risk of certain forms of cancer. The study was published on December 13, 2012, in the American Journal of Human Genetics.

Related Links:

Cleveland Clinic
Lerner Research Institute's Genomic Medicine Institute



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.